TCTN3 Antibody

What is TCTN3 and why is it important in research?

TCTN3 (tectonic family member 3) is a type I membrane protein that belongs to the tectonic family, which includes TCTN1, TCTN2, and TCTN3. It functions as a component of the tectonic-like complex localized at the transition zone of primary cilia, acting as a barrier preventing diffusion of membrane proteins between ciliary and non-ciliary compartments . TCTN3 is critical for proper Sonic Hedgehog (SHH) signaling transduction, as demonstrated by its role in GLI3 processing . Research interest in TCTN3 has grown significantly due to its implications in ciliopathies such as Joubert syndrome, Meckel syndrome, and Orofaciodigital syndrome type IV .

Which epitopes should I target when selecting a TCTN3 antibody for my research?

When selecting a TCTN3 antibody, consider targeting conserved domains based on your specific applications and species of interest. Available antibodies target various regions including:

• C-terminal region (AA 540-590)

• Middle region (varying by manufacturer)

• Internal regions

For cross-species reactivity (human, mouse, rat), antibodies targeting the middle region or C-terminus often show better conservation. For specific human applications, antibodies targeting AA 348-472 have demonstrated effectiveness in western blot and immunofluorescence applications .

What applications are TCTN3 antibodies validated for?

TCTN3 antibodies have been validated for multiple applications with the following recommended dilutions:

Note that optimal antibody dilutions may vary between tissue types and preparation methods. It is recommended to perform a dilution series to determine optimal concentration for each experimental system .

How should I optimize TCTN3 antibody conditions for immunohistochemistry of neural tissues?

For optimal TCTN3 detection in neural tissues, consider the following protocol adjustments:

• Antigen retrieval: Based on validation data, TE buffer at pH 9.0 is recommended for TCTN3 epitope recovery. Alternatively, citrate buffer at pH 6.0 may be used but with potentially lower signal intensity .

• For neural tissues specifically, which express TCTN3 in ciliated neuronal cells:

  • Use fresh frozen or lightly fixed tissues when possible (prolonged fixation may mask epitopes)

  • Consider using permeabilization optimization with 0.1-0.3% Triton X-100

  • Employ signal amplification methods for detecting low-abundance TCTN3 in specific neuronal populations

  • Use neuron-specific co-staining (such as NeuN or βIII-tubulin) to verify cell-type specificity

• Perform appropriate controls, including both positive controls (embryonic tissues known to express TCTN3) and negative controls (TCTN3 knockout tissues or peptide competition) .

What are the best experimental designs to study TCTN3 interactions with other transition zone proteins?

To effectively study TCTN3 interactions with other transition zone proteins:

• Co-immunoprecipitation approach:

  • Use cell lysates prepared with mild detergents (0.5% NP-40 or 1% digitonin) to preserve protein complexes

  • Pull down with TCTN3 antibody and blot for interacting proteins (NPHP1, MKS proteins)

  • Perform reciprocal IP with antibodies against suspected interacting proteins

• Proximity labeling methods:

  • BioID or TurboID fusion with TCTN3 to identify proximal interacting proteins

  • APEX2-based proximity labeling in living cells

• Structured visualization approach:

  • Super-resolution microscopy with dual antibody labeling

  • Preferably use antibodies from different host species to avoid cross-reactivity

  • Analyze co-localization with quantitative metrics (Pearson's correlation coefficient)

Research has demonstrated TCTN3 interactions with NPHP1, which has anti-apoptotic properties, suggesting potential regulatory functions beyond ciliary structure maintenance .

How can I accurately assess TCTN3's role in the Sonic Hedgehog signaling pathway?

To assess TCTN3's role in Sonic Hedgehog (SHH) signaling, implement a multi-faceted approach:

• Transcriptional reporter assays:

  • Measure Gli1 and Ptch1 transcription levels using qRT-PCR following SHH pathway activation with Smoothened Agonist (SAG)

  • Compare wild-type vs. TCTN3-depleted cells to quantify signaling efficiency

• GLI3 processing analysis:

  • Western blot analysis to assess levels of full-length GLI3 (GLI3-FL) versus cleaved repressor form (GLI3-R)

  • Important: Ensure proper sample preparation to preserve both forms (avoid prolonged storage at room temperature)

• Downstream functional assays:

  • Neural tube patterning markers: Examine distribution of Shh, Foxa2, and Nkx2.2 in neural tube sections

  • Cell proliferation and differentiation assays in TCTN3-depleted vs. control cells

• Quantitative approach:

  • Dose-response curves to varying concentrations of SHH pathway agonists

  • Time-course experiments to determine kinetics of pathway activation and inhibition

Research has demonstrated that TCTN3-mutated fibroblasts exhibit decreased GLI3-FL and increased GLI3-R, indicating enhanced SHH signal repression—opposite to what is observed in Tctn1-/- mice, suggesting complementary rather than redundant functions of TCTN proteins .

How do I distinguish between direct effects of TCTN3 on ciliogenesis versus indirect effects on signaling pathways?

To differentiate direct versus indirect effects of TCTN3:

• Sequential analysis approach:

  • First assess cilia formation using acetylated α-tubulin (axoneme marker) and pericentrin or γ-tubulin (basal body marker)

  • Then evaluate ciliary composition using antibodies against ciliary membrane proteins

  • Finally measure pathway activity (SHH, Wnt, etc.) using reporter assays

• Tissue-specific analysis:

  • Compare tissues where TCTN3 loss affects ciliogenesis versus tissues where cilia form but function abnormally

  • For example, TCTN3 mutations allow cilia formation in kidney epithelial cells but disrupt SHH signaling

• Rescue experiments:

  • Design rescue constructs with mutations in specific TCTN3 domains

  • Test ability to restore ciliogenesis versus signaling function separately

  • Use inducible expression systems to control timing of rescue

• Membrane diffusion measurements:

  • Track fluorescently tagged membrane proteins through the transition zone

  • Compare diffusion rates between wild-type and TCTN3-deficient cells

Research shows that TCTN3 is not necessary for cilia biogenesis in kidney tubules but is essential for SHH signal transduction, suggesting its primary role may be in regulating ciliary membrane composition rather than structural formation .

How do I resolve discrepancies between TCTN3 antibody signals in different cell types or experimental conditions?

When facing discrepancies in TCTN3 antibody signals:

• Epitope accessibility considerations:

  • Different fixation methods may affect epitope exposure

  • Cell type-specific post-translational modifications might mask epitopes

  • Try multiple antibodies targeting different TCTN3 regions

• Expression level verification:

  • Perform parallel qRT-PCR to confirm TCTN3 mRNA levels

  • Use multiple antibodies targeting different epitopes to validate protein expression

  • Consider cell cycle-dependent expression patterns

• Technical optimization:

  • For western blots: Adjust lysis conditions (RIPA vs. gentler buffers)

  • For immunostaining: Optimize permeabilization and blocking conditions

  • Test different antigen retrieval methods (heat-induced vs. enzymatic)

• Specificity controls:

  • Use TCTN3 knockout or knockdown samples as negative controls

  • Perform peptide competition assays with the immunizing peptide

  • Validate with recombinant TCTN3 expression systems

Observed molecular weight of TCTN3 is approximately 66 kDa, which matches the calculated molecular weight based on the 607 amino acid sequence .

How should I interpret complex phenotypes in TCTN3-deficient models versus single pathway perturbations?

Interpreting complex phenotypes in TCTN3-deficient models requires a systematic approach:

• Comparative phenotyping strategy:

  • Compare TCTN3-deficient phenotypes with phenotypes of known pathway components (e.g., Gli3, Smo, Ptch1 mutants)

  • Analyze phenotypic overlap and distinct features to map pathway relationships

  • Consider the timing of phenotype onset for developmental sequence insights

• Multi-pathway analysis:

  • Beyond SHH, examine Wnt, PDGF, and other ciliary-dependent pathways

  • Look for synergistic or antagonistic effects between pathway perturbations

  • Use pathway-specific readouts to dissect complex phenotypes

• Tissue-specific considerations:

  • Different tissues show varying dependencies on TCTN3 function

  • Neural tube patterning relies heavily on TCTN3 for SHH signaling

  • Compare multiple tissue types within the same model organism

• Human-mouse comparative approach:

  • Analyze phenotypic spectra in human TCTN3 mutations versus mouse models

  • Reconcile differences by considering genetic background effects and compensatory mechanisms

  • Note that human TCTN3 mutations cause spectrum from viable Joubert syndrome to severe OFD IV phenotypes

TCTN3 knockout mice show prenatal lethality, microphthalmia, polysyndactyly, and neural tube defects, while human patients with TCTN3 mutations exhibit phenotypes ranging from Joubert syndrome to more severe syndromes combining features of Meckel and OFD IV syndromes .

How can TCTN3 antibodies be used to investigate the dynamics of transition zone assembly during ciliogenesis?

To investigate transition zone assembly dynamics:

• Time-resolved immunofluorescence approach:

  • Synchronize cells and collect at defined intervals during ciliogenesis

  • Co-stain for TCTN3 and other transition zone proteins (MKS, NPHP complex components)

  • Quantify recruitment timing and sequence using live-cell imaging with tagged proteins

• Protein turnover analysis:

  • Use SNAP-tag or HaloTag fusion proteins to pulse-chase label TCTN3

  • Determine protein half-life and turnover rates at the transition zone

  • Compare stability in different cellular contexts or disease states

• Super-resolution microscopy techniques:

  • Implement STORM or PALM imaging to resolve nanoscale organization

  • Track changes in TCTN3 distribution during cilia assembly and disassembly

  • Correlate with functional transport across the transition zone barrier

• Experimental manipulation:

  • Use optogenetic approaches to manipulate TCTN3 localization in real-time

  • Apply acute inhibition of transport pathways to assess dynamic responsibilities

Research indicates that the tectonic complex regulates membrane protein composition in photoreceptors by acting as a physical barrier to slow down membrane protein diffusion through the transition zone .

What are the most promising approaches to study TCTN3's role in neurological disease models?

For investigating TCTN3 in neurological disease models:

• Conditional knockout strategies:

  • Use tissue-specific or inducible Cre/loxP systems to delete TCTN3 in specific neural populations

  • Ta3fl/fl;NesCre conditional knockout mice show postnatal defects including ataxia and hydrocephaly, making them valuable models for human ciliopathies

• Patient-derived models:

  • Generate iPSCs from patients with TCTN3 mutations

  • Differentiate into neural organoids to study 3D tissue architecture

  • Compare with gene-edited isogenic control lines

• High-content phenotypic screening:

  • Measure multiple parameters of neuronal development and function

  • Assess cell migration, morphology, and electrophysiological properties

  • Identify compound modifiers of TCTN3-related phenotypes

• In vivo imaging approaches:

  • Implement cranial window techniques for longitudinal imaging

  • Monitor neuronal migration, connectivity, and activity patterns

  • Correlate with behavioral phenotypes relevant to human ciliopathies

Studies in Ta3fl/fl;NesCre mice have shown defects in the proliferation, organization, morphology, and migration of both neuronal and glial cells, recapitulating neurological traits seen in human ciliopathies like Joubert Syndrome .

How can I design experiments to investigate potential non-ciliary functions of TCTN3?

To investigate potential non-ciliary TCTN3 functions:

• Subcellular fractionation approach:

  • Separate ciliary from non-ciliary fractions with biochemical methods

  • Quantify TCTN3 distribution across multiple cellular compartments

  • Identify novel interacting partners in non-ciliary fractions

• PI3K/Akt pathway investigation:

  • Examine TCTN3's role in PI3K/Akt signaling independent of SHH

  • Use phospho-specific antibodies against Akt and downstream targets

  • Test whether Akt activators like SC79 can rescue phenotypes in TCTN3-deficient cells

• Cell death pathway analysis:

  • Investigate changes in apoptosis-related proteins (Bcl-2, Bax, cleaved PARP1)

  • Determine whether TCTN3 loss affects cell survival through NPHP1 interaction

  • Assess whether apoptotic effects occur before or independent of ciliary defects

• Cell cycle and proliferation studies:

  • Synchronize cells and analyze cell cycle progression with flow cytometry

  • Examine potential interactions between TCTN3 and cell cycle regulators

  • Investigate whether TCTN3 has cilia-independent roles at centrosomes or mitotic spindles